H.C. Wainwright analyst Edward White reiterated a Buy rating on Karyopharm and maintained a $40 price target after the company announced that the FDA accepted the company's NDA filing for Xpovio in patients with relapsed or refractory diffuse large B-Cell lymphoma after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation and that its request for Priority Review was also granted. In addition, Karyopharm plans to submit an MAA to the EMA for Xpovio in r/r DLBCL in 2020, which could coincide with a multiple myeloma filing in Europe based on the Phase 3 BOSTON data for a more seamless submission process, White tells investors in a research note. The analyst expects Xpovio could receive approval for r/r DLBCL by the PDUFA date and launch shortly thereafter and estimates Xpovio sales of $3.6M in 2020 and $58.7M in 2026 for the DLBCL indication.